New mRNA-Based Medicine for Peanut Allergies: Hope for Millions of Americans

Peanut allergies, mRNA, University of California Los Angeles (UCLA), groundbreaking treatment, nanoparticle, liver-targeting lipid nanoparticle (LNP), mRNA-encoded peanut allergen epitopes, immune tolerance, nucleotide sequences, Ara h2, MHC-II targeting sequence, microfluidics, ionizable cationic lipid, ELISpot assays, IL-10-producing Tregs, biodistribution, spleen, prophylactic administration, crude peanut allergen extract, breakthrough, revolutionize, relief, medical science,Best pizza shop near me,best clothing shop nearme , Best medine shop in vikhroli,shop in vikhroli.
Image Credits : Medscape


Peanut allergies affect nearly three million Americans, with approximately one in every fifty children suffering from this potentially life-threatening condition. However, researchers at the University of California, Los Angeles (UCLA) have developed a groundbreaking treatment for peanut allergies using mRNA, inspired by the success of mRNA-based COVID-19 vaccines.

Dr. André Nel, co-corresponding author of the research paper, stated, "As far as we can find, mRNA has never been used for an allergic disease. We've shown that our platform can work to calm peanut allergies, and we believe it may be able to do the same for other allergens, in food and drugs, as well as autoimmune conditions."

The treatment involves delivering mRNA inside a nanoparticle to the liver, where it targets specific cells to tolerate peanut proteins. In tests conducted on mice, the mRNA-based medicine not only reversed peanut allergies but also prevented the development of severe conditions. The nanoparticle treatment was shown to improve the animals' peanut tolerance, paving the way for potential clinical trials in the near future.

With a few more lab studies, the mRNA-based treatment could be ready for clinical trials within three years, according to the authors of the research. The team also plans to investigate whether these nanoparticles could be used to treat other conditions, such as type 1 diabetes. Currently, there is only one approved treatment for type 1 diabetes, so this potential new treatment could represent a significant advancement in medical science.

The researchers used a liver-targeting lipid nanoparticle (LNP) platform to deliver mRNA-encoded peanut allergen epitopes to liver sinusoidal endothelial cells (LSECs), which are known to induce regulatory T-cells (Tregs) that can help establish immune tolerance. The mRNA strand used in the treatment included nucleotide sequences encoding for nonallergenic T-cell epitopes identified in the dominant peanut allergen, Ara h2. These epitopes were inserted in the mRNA strand downstream of an MHC-II targeting sequence, and the mRNA was constructed with 5' and 3' capping sequences, a PolyA tail, and uridine substitution. The LNPs were synthesized using microfluidics and an ionizable cationic lipid, with a lipid-anchored mannose ligand for LSEC targeting.

The biodistribution of the LNPs to the liver was confirmed through in vivo imaging, and ELISpot assays showed an increase in IL-10-producing Tregs in the spleen. Prophylactic administration of encapsulated Ara h2 epitopes induced tolerogenic effects in mice sensitized to and challenged with crude peanut allergen extract.

This breakthrough in mRNA-based medicine for peanut allergies offers hope for millions of Americans who suffer from this condition. If successful, it could revolutionize the treatment of peanut allergies and potentially other allergies and autoimmune conditions in the future. As further research progresses, this innovative treatment could bring relief to those with peanut allergies and pave the way for new possibilities in medical science. 

Comments

Post a Comment

Popular posts from this blog

Beyond Ozempic: The Next Generation of Weight-Loss Drugs Set to Revolutionize Obesity Treatment

Image
IMAGE CREDITS: Medical News Today  In recent months, the weight-loss drug Ozempic, which contains semaglutide, has taken the world by storm, with Hollywood celebrities and TikTok influencers hailing it as a "revolutionary" and "game-changing" treatment for obesity. Semaglutide has been proven to lead to significant weight loss in many individuals, making it a promising option for those struggling with obesity. However, let's not jump ahead too quickly - Ozempic has its limitations, including the need for weekly injections, potential side effects, and the cost of long-term treatment. Additionally, while Ozempic has been approved by the FDA as a diabetes medication, a higher dose of semaglutide, marketed as Wegovy, has been approved for weight loss. Despite its current dominance in the weight-loss market, semaglutide may soon face competition from even more potent and powerful medications. The demand for effective obesity drugs has spurred a race in the pharmaceut
Read more

Reliance Jio Partners with SES to Launch Jio Space Technology Limited, Promising Lightning-Fast Satellite-Based Broadband in India at 100Gbps Speeds

Image
 Reliance Jio, one of India's leading telecommunications companies, has joined forces with Luxembourg-based SES to unveil an exciting new joint venture, Jio Space Technology Limited. This partnership aims to revolutionize broadband services in India using cutting-edge satellite technology, offering speeds of up to 100Gbps. The move comes in the wake of Elon Musk's Starlink facing regulatory hurdles in India, creating an opportunity for local players to step up and fill the gap. Jio Space Technology Limited, in which Reliance Jio holds a majority stake of 51%, will harness a combination of geostationary (GEO) and medium earth orbit (MEO) satellite constellations to deliver lightning-fast broadband to enterprises, mobile backhaul, and retail customers. With multi-gigabit links and capacity, this broadband service promises to significantly enhance digital services and applications across the country. "We are excited to embark on this journey with SES to bring cutting-edge sat
Read more

Shifting Tides: Apple's Unprecedented Layoffs in a Changing Tech Landscape

Image
  IMAGE CREDITS : KSNV Apple, known for its no-layoff policy, is reportedly making cuts in its retail division, signaling a shift in its approach to operations. Bloomberg and Business Insider report that while the number of employees affected is likely to be small, it marks a departure from Apple's previous stance of avoiding layoffs, setting it apart from other tech giants like Google, Amazon, Meta, and Microsoft who have announced significant job cuts. The layoffs are said to be in Apple's retail building and upkeep division, with affected employees given the option to apply for other positions within the company until the end of the week. For those unable to find a new role, Apple is reportedly offering up to four months of severance pay. While Apple has been cutting costs in various ways, including laying off contractors and delaying projects, CEO Tim Cook has emphasized that layoffs are a last resort. The news of Apple's layoffs raises questions about the changing land
Read more